Anti‐infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition · 2024-02 · 78 (2) · 261-271
DOI: 10.1002/jpn3.12074 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 27.12.2023. Verfasst von Naamah Zitomersky und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
Infliximab (IFX) use is limited by loss of response often due to the development of anti‐IFX antibodies and low drug levels.
Methods
We performed a single center prospective observational cohort study of pediatric and young adult subjects with inflammatory bowel disease (IBD) on IFX with over 3 years of follow‐up. Infliximab levels (IFXL) and antibodies to infliximab (ATI) were measured throughout the study. Subjects were followed until IFX was discontinued.
Results
We enrolled 219 subjects with IBD (184: Crohn's disease; 33: Ulcerative colitis; and 2 Indeterminant colitis; 84 female, median age 14.4 years, 37% on concomitant immunomodulator). Nine hundred and nineteen serum samples (mean 4.2 ± 2.1 per patient) were tested for IFXL and ATI. During the study, 31 (14%) subjects discontinued IFX. Sixty patients had ATI. Twenty‐two of those 60 patients with ATI discontinued IFX; 14 of 31 patients who discontinued IFX had detectable ATI at study onset. The combination of ATI and IFXL < 5 µg/mL at study entry was associated with the highest risk of drug discontinuation (hazard ratios [HR] ATI 4.27 [ p < 0.001] and IFXL < 5 µg/mL [HR]: 3.2 p = 0.001). Patients with IFXL 5–10 µg/mL had the lowest rate of discontinuation (6%). IFX dose escalation eliminated ATI in 21 of 60 subjects.
Conclusions
ATI is a strong predictor of needing to stop IFX use and inversely correlates with IFXL. Detection of ATI during therapeutic drug monitoring postinduction but also periodically during maintenance therapy identifies individuals who may benefit from IFX dose escalation and/or the addition of an immunomodulator, as these interventions may reduce or eliminate ATI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts, USA.
- Prometheus Laboratories Inc, San Diego, California, USA.
- ProciseDx LLC, San Diego, California, USA.
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Zitomersky, N., Chi, L., Liu, E., Bray, K. R., Papamichael, K., Cheifetz, A. S., Snapper, S. B., Bousvaros, A., & Silvester, J. A. (2024). Anti‐infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition, 78(2), 261-271. https://doi.org/10.1002/jpn3.12074
Vancouver
Zitomersky N, Chi L, Liu E, Bray KR, Papamichael K, Cheifetz AS, et al. Anti‐infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2024;78(2):261-271. doi:10.1002/jpn3.12074
BibTeX
@article{Zitomersky2024,
author = {Zitomersky, Naamah and Chi, Lisa and Liu, Enju and Bray, Kurtis R and Papamichael, Konstantinos and Cheifetz, Adam S and Snapper, Scott B and Bousvaros, Athos and Silvester, Jocelyn A},
title = {Anti‐infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
volume = {78},
number = {2},
pages = {261--271},
doi = {10.1002/jpn3.12074}
}
EUVIMED